DermTech, Inc. (DMTK)
| Market Cap | 991.38M |
| Revenue (ttm) | 5.35M |
| Net Income (ttm) | -30.92M |
| Shares Out | 18.93M |
| EPS (ttm) | -3.34 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $39.00 |
| Previous Close | $39.67 |
| Change ($) | -0.67 |
| Change (%) | -1.69% |
| Day's Open | 39.74 |
| Day's Range | 38.04 - 41.44 |
| Day's Volume | 704,190 |
| 52-Week Range | 8.98 - 41.44 |
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider bu...
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that SKIN has...
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that non-inva...
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (Nasdaq: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the closing o...
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (Nasdaq: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the pricing o...
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (Nasdaq: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that it has c...
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the appointme...
The biotech's skin cancer diagnostic tool is a significant improvement over the standard of care.
The company's genomic test for melanoma won another positive coverage decision.
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that Geisinge...
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ:DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that DermTech ...
DermTech (DMTK) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
DermTech's PLA stickers can help to diagnose melanoma despite being lower cost, more accurate, and less invasive compared to standard surgical biopsies.With 4-4.5mil surgical biopsies per year...
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the topline r...
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its inclusion...
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it has entere...
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the presentat...
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it has entere...
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech Presents New Clinical Research Abstract at the 2020 Fall Clinical Dermatology Conference
Great things appear to be in store for these rising stars.
DermTech, Inc. (DMTK) CEO John Dobak on Q3 Results - Earnings Call Transcript
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported unaudited fina...
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced to...
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech to Announce Third Quarter 2020 Financial Results on November 10, 2020
Discover how these three companies could change the face of healthcare.
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech Announces Appointment of Chief Scientific Officer
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech to Participate in Upcoming Investor Conferences
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc.
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that as part ...
This week has been a successful one for markets, with the S&P 500 entering positive territory on the year. If you’re looking to hedge the rally, our deep learning algorithms have identified se...
Shares of precision dermatology company DermTech Inc (NASDAQ: DMTK) are rallying Thursday after receiving Medicare coverage for its diagnostic test to rule out skin cancer.
About DMTK
DermTech, a molecular diagnostic company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. The company offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. It also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. The comp... [Read more...]
| Industry Diagnostics & Research | |
| CEO Dr. John D. Dobak | Employees 60 |
| Stock Exchange NASDAQ | Ticker Symbol DMTK |
Financial Performance
In 2019, DermTech's revenue was $3.36 million, an increase of 37.76% compared to the previous year's $2.44 million. Losses were -$19.69 million, 96.8% more than in 2018.
Analyst Forecasts
According to 4 analysts, the average rating for DermTech stock is "Strong Buy." The 12-month stock price forecast is 36.33, which is a decrease of -6.85% from the latest price.